Fundz

Liquidia Corporation Announces $100 Million In New Financings

PUBLIC · LQDAJan 04, 2024

Amount Raised

$100 Million

Round Type

Funding Round

MorrisvilleManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiotechnology Research

Description

Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that the Company has entered into agreements for an additional $100 million in capital between two transactions with funds associated with Patient Square Capital and HealthCare Royalty (HCRx), respectively.

Who else raised in Therapeutics and Pharmaceutical around the same time

Companies in the same sectors as Liquidia that raised within 45 days of this round, from Fundz verified event records.

  • AIM ImmunoTech raised $3.3M (Seed) on February 16, 2024.
  • valisure llc raised $4M (Seed) on February 16, 2024.
  • Sudo Biosciences raised $147M (Series B) on February 13, 2024.
  • Calluna Pharma raised $82M (Series A) on January 23, 2024.
  • Ratio Therapeutics raised $50M (Series B) on January 17, 2024.
  • OnCusp Therapeutics raised $100M (Series A) on January 4, 2024.

Who to call at Liquidia, and when

A new round usually means Liquidia is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Liquidia raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Liquidia, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Liquidia. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Liquidia

Location

419 Davis Drive, Suite 100

Morrisville, North Carolina, United States

About

Liquidia is a biopharmaceutical company focused on the development and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of pulmonary arterial hypertension (PAH). Our pipeline is focused on the development of two product candidates using our PRINT® Technology platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Our subsidiary, Liquidia PAH (formerly RareGen), generates revenue pursuant to a promotional agreement between RareGen and Sandoz, sharing profit derived from the sale of the first-to-file fully substitutable generic treprostinil injection, or Treprostinil Injection, in the United States.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Liquidia raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsROGER J., Chief Executive Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Liquidia's next move

See what Strategic adds

Liquidia raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.